Clinical trial
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
NCT00316420 · Swedish Medical Center, Other · Completed
Key facts
| NCT number | NCT00316420 |
|---|---|
| Title | Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer |
| Official title | Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma |
| Lead sponsor | Swedish Medical Center, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda), Gemcitabine |
| Enrollment | 20 |
| Start date | Dec 1, 2003 |
| Primary completion | Feb 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Apr 20, 2006 |
| Last update posted | Mar 8, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: